Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 1
1987 1
1988 1
1989 6
1990 1
1991 7
1992 1
1993 4
1994 1
1995 4
1996 6
1997 5
1998 13
1999 6
2000 8
2001 7
2002 16
2003 14
2004 15
2005 16
2006 27
2007 17
2008 26
2009 30
2010 48
2011 46
2012 43
2013 44
2014 45
2015 51
2016 40
2017 32
2018 42
2019 41
2020 44
2021 31
2022 33
2023 31
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

696 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY; South China Breast Cancer Group (SCBCG). Wang X, et al. JAMA. 2021 Jan 5;325(1):50-58. doi: 10.1001/jama.2020.23370. JAMA. 2021. PMID: 33300950 Free PMC article. Clinical Trial.
After a median follow-up of 61 months (interquartile range, 44-82), 94 events were observed, including 38 events (37 recurrences and 32 deaths) in the capecitabine group and 56 events (56 recurrences and 40 deaths) in the observation group. ...The most common capeci …
After a median follow-up of 61 months (interquartile range, 44-82), 94 events were observed, including 38 events (37 recurrences and …
Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A, Sharma A, Bakhshi S, Kumar A, Sharma V, Malik PS, Pramanik R, Gogia A, Prasad CP, Sehgal T, Gund S, Dev A, Cheung WY, Pandey RM, Kumar S, Gupta I, Batra A; D-TORCH Trial Investigators. Santhosh A, et al. J Clin Oncol. 2024 May 20;42(15):1821-1829. doi: 10.1200/JCO.23.01730. Epub 2024 Feb 27. J Clin Oncol. 2024. PMID: 38412399 Clinical Trial.
PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. ...RESULTS: In total, 264 patients were randomly assigned to receive topical diclofenac gel (n = 131) or placebo (n = 133). Grade 2 or 3 HFS was observed in 3.8% of parti …
PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. ...RESULTS: In total, 264 patients we …
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY, Sun Y, Ma J. Chen YP, et al. Lancet. 2021 Jul 24;398(10297):303-313. doi: 10.1016/S0140-6736(21)01123-5. Epub 2021 Jun 7. Lancet. 2021. PMID: 34111416 Clinical Trial.
Safety was assessed in all patients who received at least one dose of capecitabine or who had commenced observation. This trial is registered with ClinicalTrials.gov, NCT02958111. ...Grade 3 adverse events were reported in 35 (17%) of 201 patients in the metronomic capecit …
Safety was assessed in all patients who received at least one dose of capecitabine or who had commenced observation. This trial is re …
Predicting Response to Anthracyclines in Ovarian Cancer.
Ferrero A, Borghese M, Restaino S, Puppo A, Vizzielli G, Biglia N. Ferrero A, et al. Int J Environ Res Public Health. 2022 Apr 2;19(7):4260. doi: 10.3390/ijerph19074260. Int J Environ Res Public Health. 2022. PMID: 35409939 Free PMC article. Review.
Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. Prediction of response to anthracyclines is challenging and no markers can predict certain therapeutic success. The current narrativ …
Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. Pre …
Capecitabine induced fingerprint changes.
Yaghobi Joybari A, Azadeh P, Ghiasi HA, Amouzegar A, Yaseri M, Amini A, Farasatinasab M, Mokhtari M. Yaghobi Joybari A, et al. J Clin Pharm Ther. 2019 Oct;44(5):780-787. doi: 10.1111/jcpt.13003. Epub 2019 Jun 29. J Clin Pharm Ther. 2019. PMID: 31254478
RESULTS AND DISCUSSION: Thirty-seven patients were enrolled in the capecitabine group and 34 in a comparison group. Fingerprint changes were observed in 25 (67.6%) of the 37 patients in the capecitabine group and none in the comparison group. ...
RESULTS AND DISCUSSION: Thirty-seven patients were enrolled in the capecitabine group and 34 in a comparison group. Fingerprint changes were …
Topical non-occlusive polymers in hand-foot syndrome.
Fabbrocini G, Cristaudo A, Ionescu MA, Panariello L, Robert G, Pellicano M, Ayala F. Fabbrocini G, et al. G Ital Dermatol Venereol. 2018 Apr;153(2):165-171. doi: 10.23736/S0392-0488.17.05709-1. G Ital Dermatol Venereol. 2018. PMID: 29564873
BACKGROUND: Many cytotoxic and biological drugs are cause of severe dermatological side effects, such as hand-foot syndrome (HFS) and hand-foot skin reaction (HFSR). Oncologic patients with HFS or HFSR presents relevant symptoms that interferes with daily act …
BACKGROUND: Many cytotoxic and biological drugs are cause of severe dermatological side effects, such as hand-foot syndrome …
Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. McLellan B, et al. Ann Oncol. 2015 Oct;26(10):2017-26. doi: 10.1093/annonc/mdv244. Epub 2015 Jun 1. Ann Oncol. 2015. PMID: 26034039 Free PMC article. Review.
BACKGROUND: Regorafenib is an orally available, small-molecule multikinase inhibitor with international marketing authorizations for use in colorectal cancer and gastrointestinal stromal tumors. In clinical trials, regorafenib showed a consistent and predictable adverse-ev …
BACKGROUND: Regorafenib is an orally available, small-molecule multikinase inhibitor with international marketing authorizations for use in …
The safety of apatinib for the treatment of gastric cancer.
Geng R, Song L, Li J, Zhao L. Geng R, et al. Expert Opin Drug Saf. 2018 Nov;17(11):1145-1150. doi: 10.1080/14740338.2018.1535592. Epub 2018 Oct 24. Expert Opin Drug Saf. 2018. PMID: 30324820 Review.
Apatinib is well tolerated, and its most common adverse effects include hand-foot syndrome, hypertension, proteinuria and neutropenia. Its major grade 3/4 adverse effect is hand-foot syndrome. ...Additionally, the early presence of antian …
Apatinib is well tolerated, and its most common adverse effects include hand-foot syndrome, hypertension, proteinuria a …
Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study.
Shou L, Chen J, Shao T, Zhang Y, Zhao S, Chen S, Shu Q. Shou L, et al. Support Care Cancer. 2023 Jun 5;31(7):375. doi: 10.1007/s00520-023-07830-3. Support Care Cancer. 2023. PMID: 37273007
Notably, we found that HFSR was classified into three consecutive stages: erythematous lesion, yellow hyperkeratotic lesion with surrounding erythema, and hyperkeratotic lesion. Inflammation was observed in the first two stages of HFSR, but disappeared in the third stage; …
Notably, we found that HFSR was classified into three consecutive stages: erythematous lesion, yellow hyperkeratotic lesion with surrounding …
Hand-foot syndrome following decitabine.
Ali AM, Jacoby M, Welch JS. Ali AM, et al. Ann Hematol. 2016 Feb;95(3):535-6. doi: 10.1007/s00277-015-2546-1. Epub 2015 Nov 6. Ann Hematol. 2016. PMID: 26542147 Free PMC article.
We observed a case of Hand-Foot Syndrome (HFS) in a patient treated with decitabine. HFS has not previously been associated with decitabine, although it has been observed following treatment with the structurally similar pyrimidine analogue cyta …
We observed a case of Hand-Foot Syndrome (HFS) in a patient treated with decitabine. HFS has not previously been …
696 results